BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
Art Still, former Kansas City Chiefs player, was diagnosed with ATTR amyloidosis, a rare heart condition more common in Black men. He shares symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback